Products Categories
CAS No.: | 302-95-4 |
---|---|
Name: | Sodium deoxycholate |
Molecular Structure: | |
|
|
Formula: | C24H39NaO4 |
Molecular Weight: | 414.561 |
Synonyms: | 5b-Cholan-24-oic acid, 3a,12a-dihydroxy-, monosodium salt (8CI);Deoxycholic acidmonosodium salt;Deoxycholic acid sodium salt;Desoxycholate sodium;Desoxycholic acid sodium salt;NSC 681065;Sodium 3a,12a-dihydroxy-5b-cholanate;Sodium 7-deoxycholate;Sodium deoxycholate;Sodium desoxycholate;Sodium Deoxycholic acid; |
EINECS: | 206-132-7 |
Density: | 1.129 g/cm3 |
Melting Point: | 357-365 °C |
Boiling Point: | 547.148 °C at 760 mmHg |
Flash Point: | 298.768 °C |
Solubility: | 330 g/L (15 °C) in water |
Appearance: | white to cream crystalline powder |
Hazard Symbols: |
![]() |
Risk Codes: | 22-37 |
Safety: | 22 |
PSA: | 80.59000 |
LogP: | 3.14320 |
sodium cholate
Conditions | Yield |
---|---|
In tetrahydrofuran |
Conditions | Yield |
---|---|
With disodium hydrogenphosphate; sodium hydroxide pH=8.3; |
sodium cholate
12α-hydroxy-3-oxochol-4-en-24-oic acid
Conditions | Yield |
---|---|
With Pseudomonas mendocina ECS10 In water at 28℃; for 24h; Microbiological reaction; | 95% |
Conditions | Yield |
---|---|
In dichloromethane; water for 48h; | 92% |
Conditions | Yield |
---|---|
With sulfuric acid for 3h; Heating; | 91% |
sodium cholate
1,3,5-tris(bromomethyl)-2,4,6-triethylbenzene
C87H138O12
Conditions | Yield |
---|---|
In N,N-dimethyl-formamide at 75 - 80℃; Inert atmosphere; | 87% |
1-naphthylmethyl 3α,12α-bis(chloroacetyloxy)-5β-cholan-24-oate
sodium cholate
Conditions | Yield |
---|---|
In N,N-dimethyl-formamide at 60℃; for 7h; | 86% |
Conditions | Yield |
---|---|
In toluene Inert atmosphere; Reflux; | 84.6% |
Conditions | Yield |
---|---|
In N,N-dimethyl-formamide at 75 - 80℃; Inert atmosphere; | 84% |
Conditions | Yield |
---|---|
In toluene Inert atmosphere; Reflux; | 83.9% |
The IUPAC name of Sodium deoxycholate is sodium (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate. With the CAS registry number 302-95-4 and EINECS 206-132-7, it is also named as 3-alpha,12-alpha-Dihydroxy-5-beta-cholan-24-oic acid sodium salt. The product's categories are Bile Salts Detergents; Anionic; Detergents; Detergents A to Z; Steroids. It is white to cream crystalline powder which is a bile acid formed by bacterial action from cholate. What's more, it is used in the preparation of bacteria culture medium. Additionally, this chemical should be sealed in the container and stored in the cool and dry place at the normal temperature.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 4.76; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 3.946; (4)ACD/LogD (pH 7.4): 2.149; (5)ACD/BCF (pH 5.5): 374.136; (6)ACD/BCF (pH 7.4): 5.973; (7)ACD/KOC (pH 5.5): 1416.189; (8)ACD/KOC (pH 7.4): 22.61; (9)#H bond acceptors: 4; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 6; (12)Polar Surface Area: 77.76 Å2; (13)Index of Refraction: 1.543; (14)Molar Refractivity: 109.65 cm3; (15)Molar Volume: 347.857 cm3; (16)Polarizability: 43.469×10-24 cm3; (17)Surface Tension: 46.016 dyne/cm; (18)Density: 1.129 g/cm3; (19)Flash Point: 298.768 °C; (20)Enthalpy of Vaporization: 95.005 kJ/mol; (21)Boiling Point: 547.148 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.
When you are using this chemical, please be cautious about it as the following:
It is not only harmful if swallowed, but also very toxic in contact with skin. So people should not breathe dust.
People can use the following data to convert to the molecule structure.
1. SMILES:C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
2. InChI:InChI=1/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
3. InChIKey:KXGVEGMKQFWNSR-LLQZFEROBK
The following are the toxicity data which has been tested.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 36mg/kg (36mg/kg) | BEHAVIORAL: EXCITEMENT LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Eisei Shikenjo Hokoku. Bulletin of the Institute of Hygienic Sciences. Vol. (103), Pg. 29, 1985. |
mouse | LD50 | intravenous | 107mg/kg (107mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 90, Pg. 18, 1952. | |
mouse | LD50 | oral | 1050mg/kg (1050mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE | Eisei Shikenjo Hokoku. Bulletin of the Institute of Hygienic Sciences. Vol. (103), Pg. 29, 1985. |
mouse | LD50 | subcutaneous | 815mg/kg (815mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 45, 1969. |
rabbit | LDLo | intravenous | 15mg/kg (15mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA BLOOD: OTHER CHANGES | Zeitschrift fuer die Gesamte Experimentelle Medizin. Vol. 52, Pg. 779, 1926. |
rat | LD50 | intraperitoneal | 123mg/kg (123mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 45, 1969. |
rat | LD50 | intravenous | 150mg/kg (150mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 323, 1970. | |
rat | LD50 | oral | 1370mg/kg (1370mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 45, 1969. |
rat | LD50 | subcutaneous | 2430mg/kg (2430mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Oyo Yakuri. Pharmacometrics. Vol. 3, Pg. 45, 1969. |